Takeda Pharmaceutical Co LtdNYSE:TAK
- LAST PRICE13.6200
- TODAY'S CHANGE (%)0.0500 (0.3685%)
- Bid / Lots13.2700/ 21
- Ask / Lots14.2800/ 5
- Open / Previous Close13.5700 / 13.5700
- Day Range
- 52 Week Range
- Volume373,133
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TAK |
|---|---|---|
| 09:32 ET | 23588 | 13.59 |
| 09:33 ET | 2927 | 13.59 |
| 09:35 ET | 11502 | 13.6 |
| 09:37 ET | 300 | 13.62 |
| 09:39 ET | 3857 | 13.6 |
| 09:42 ET | 900 | 13.6 |
| 09:44 ET | 2969 | 13.6 |
| 09:46 ET | 4834 | 13.6 |
| 09:50 ET | 225 | 13.59 |
| 09:51 ET | 483 | 13.595 |
| 09:53 ET | 2300 | 13.58 |
| 10:02 ET | 3635 | 13.585 |
| 10:04 ET | 1500 | 13.5895 |
| 10:06 ET | 400 | 13.585298 |
| 10:08 ET | 600 | 13.595 |
| 10:09 ET | 9469 | 13.585 |
| 10:11 ET | 300 | 13.5894 |
| 10:13 ET | 200 | 13.585 |
| 10:15 ET | 2476 | 13.59 |
| 10:18 ET | 635 | 13.59 |
| 10:20 ET | 1510 | 13.59 |
| 10:22 ET | 300 | 13.59 |
| 10:24 ET | 3636 | 13.58 |
| 10:26 ET | 371 | 13.59 |
| 10:27 ET | 1798 | 13.58 |
| 10:29 ET | 400 | 13.57 |
| 10:31 ET | 1110 | 13.575 |
| 10:33 ET | 466 | 13.579 |
| 10:36 ET | 9220 | 13.59 |
| 10:38 ET | 4126 | 13.58 |
| 10:40 ET | 811 | 13.58 |
| 10:42 ET | 1910 | 13.59 |
| 10:44 ET | 200 | 13.595 |
| 10:47 ET | 572 | 13.5975 |
| 10:49 ET | 1901 | 13.595 |
| 10:51 ET | 400 | 13.6 |
| 10:54 ET | 2883 | 13.605 |
| 10:56 ET | 200 | 13.605 |
| 10:58 ET | 600 | 13.61 |
| 11:00 ET | 626 | 13.61 |
| 11:02 ET | 300 | 13.61 |
| 11:03 ET | 20096 | 13.61 |
| 11:05 ET | 625 | 13.609 |
| 11:07 ET | 776 | 13.61 |
| 11:09 ET | 300 | 13.61 |
| 11:12 ET | 4131 | 13.605 |
| 11:14 ET | 9728 | 13.595 |
| 11:16 ET | 400 | 13.595 |
| 11:18 ET | 2228 | 13.5954 |
| 11:20 ET | 2789 | 13.595 |
| 11:21 ET | 506 | 13.595 |
| 11:23 ET | 230 | 13.5956 |
| 11:25 ET | 100 | 13.595 |
| 11:27 ET | 15499 | 13.615 |
| 11:30 ET | 2025 | 13.615 |
| 11:32 ET | 4837 | 13.615 |
| 11:34 ET | 12494 | 13.595 |
| 11:36 ET | 100 | 13.595 |
| 11:38 ET | 1637 | 13.595 |
| 11:39 ET | 244 | 13.6 |
| 11:41 ET | 1817 | 13.595 |
| 11:43 ET | 409 | 13.59 |
| 11:45 ET | 4680 | 13.595 |
| 11:48 ET | 1295 | 13.6 |
| 11:50 ET | 282 | 13.595 |
| 11:52 ET | 4138 | 13.595 |
| 11:54 ET | 672 | 13.595 |
| 11:56 ET | 1524 | 13.59 |
| 11:57 ET | 200 | 13.595 |
| 11:59 ET | 316 | 13.595 |
| 12:01 ET | 300 | 13.595 |
| 12:03 ET | 400 | 13.595 |
| 12:06 ET | 1395 | 13.6 |
| 12:08 ET | 7403 | 13.595 |
| 12:10 ET | 400 | 13.6 |
| 12:12 ET | 300 | 13.595 |
| 12:14 ET | 515 | 13.6 |
| 12:15 ET | 811 | 13.6 |
| 12:17 ET | 5516 | 13.5991 |
| 12:19 ET | 321 | 13.5963 |
| 12:21 ET | 575 | 13.5998 |
| 12:24 ET | 1855 | 13.605 |
| 12:26 ET | 3944 | 13.605 |
| 12:28 ET | 100 | 13.605 |
| 12:30 ET | 1525 | 13.605 |
| 12:32 ET | 1312 | 13.6099 |
| 12:33 ET | 1667 | 13.61 |
| 12:35 ET | 1648 | 13.615 |
| 12:37 ET | 600 | 13.62 |
| 12:39 ET | 3904 | 13.62 |
| 12:42 ET | 3117 | 13.615 |
| 12:44 ET | 800 | 13.62 |
| 12:46 ET | 1700 | 13.62 |
| 12:48 ET | 4804 | 13.625 |
| 12:50 ET | 1600 | 13.625 |
| 12:51 ET | 1971 | 13.62 |
| 12:53 ET | 12479 | 13.615 |
| 12:55 ET | 585 | 13.615 |
| 12:57 ET | 9907 | 13.61 |
| 01:00 ET | 58133 | 13.62 |
Nov 21, 2024
HUTCHMED Announces Launch by Takeda of FRUZAQLA(R) (fruquintinib) in Japan, from 11:30PM ET on Thursday Nov 21, 2024 by Dow Jones
11:30PM ET on Thursday Nov 21, 2024 by Dow Jones
Nov 4, 2024
New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD, from 8:01AM ET on Monday Nov 04, 2024 by Dow Jones
8:01AM ET on Monday Nov 04, 2024 by Dow Jones
Oct 31, 2024
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA(R) (fruquintinib) Sales by Takeda, from 4:30AM ET on Thursday Oct 31, 2024 by Dow Jones
4:30AM ET on Thursday Oct 31, 2024 by Dow JonesPress Release: HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA(R) (fruquintinib) Sales by Takeda, from 4:30AM ET on Thursday Oct 31, 2024 by Dow Jones
4:30AM ET on Thursday Oct 31, 2024 by Dow JonesDJ Takeda Pharmaceutical Posts Quarterly Net Profit, Raises Guidance -- Update, from 3:12AM ET on Thursday Oct 31, 2024 by Dow Jones
3:12AM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Takeda Pharmaceutical Co Ltd | 43.1B | 22.7x | -8.01% |
LifeVantage Corp | 180.4M | 45.8x | -14.53% |
Bavarian Nordic A/S | 2.2B | 13.4x | --- |
Xeris Biopharma Holdings Inc | 474.1M | -7.5x | --- |
Lifecore Biomedical Inc | 274.0M | 200.6x | +27.97% |
Assertio Holdings Inc | 93.3M | -1.4x | --- |
Company Information
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
Contact Information
- Headquarters
- 4F, 2-1-1, Nihombashihon-choCHUO-KU, TKY, Japan 103-8668
- Phone
- ---
- Fax
- ---
Executives
- Chairman of Board of Directors, Independent Director
- Masami Iijima
- President, Chief Executive Officer, Representative Director
- Christophe Weber
- Chief Financial Officer, Director
- Milano Furuta
- President of Research & Development, Director
- Andrew Plump
- Independent Director
- Jean-Luc Butel
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $43.1B |
|---|---|
Revenue (TTM) | $30.0B |
Shares Outstanding | 3.2B |
Dividend Yield | 2.15% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.54 |
EPS | $0.60 |
Book Value | $15.29 |
P/E Ratio | 22.7x |
Price/Sales (TTM) | 1.4 |
Price/Cash Flow (TTM) | 6.2x |
Operating Margin | 9.80% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
